Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Protara Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TARA
Nasdaq
8731
https://protaratx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Protara Therapeutics Inc
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
- May 2nd, 2024 12:00 pm
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
- Apr 5th, 2024 12:04 pm
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
- Apr 5th, 2024 12:02 pm
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
- Apr 5th, 2024 12:00 pm
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 13th, 2024 12:00 pm
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 1:00 pm
We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate
- Feb 17th, 2024 12:21 pm
Protara Therapeutics to Participate in Upcoming Investor Conferences
- Jan 31st, 2024 12:30 pm
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
- Nov 30th, 2023 1:30 pm
Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results
- Nov 3rd, 2023 1:43 pm
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
- Nov 3rd, 2023 12:00 pm
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
- Oct 23rd, 2023 12:00 pm
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
- Sep 20th, 2023 12:30 pm
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
- Sep 10th, 2023 12:14 pm
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 11:30 am
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
- Aug 3rd, 2023 12:00 pm
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
- May 15th, 2023 12:00 pm
Scroll